BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture
BioVaxys Technology Corp. (BVAXF) and SpayVac for Wildlife have expanded their License Agreement to include commercial aquaculture and farm-raised fish markets. The expansion targets a significant market opportunity in farm-raised Atlantic salmon and rainbow trout, with an annual harvest of approximately 3.28 million metric tons (800 million individual fish).
SpayVac's single-dose fertility-control vaccines offer an alternative to triploidy in aquaculture, with initial proof-of-concept trials progressing to the second phase. The technology uses a patented liposome-based delivery platform, demonstrating 4-10 years of contraceptive efficacy in various species.
The company is pursuing regulatory approval for feral horses and free-ranging deer populations, with the U.S. Bureau of Land Management (BLM) as a potential lead customer. The BLM currently manages 53,797 horses on the range, significantly above the Appropriate Management Level of 22,637, spending 66% of its $153 million budget on long-term holding costs.
BioVaxys Technology Corp. (BVAXF) e SpayVac for Wildlife hanno ampliato il loro Accordo di Licenza per includere i mercati dell'acquacoltura commerciale e del pesce allevato in fattoria. Questa espansione mira a un'importante opportunità di mercato nel salmone atlantico e nella trota iridea allevati in fattoria, con una raccolta annua di circa 3,28 milioni di tonnellate metriche (800 milioni di esemplari).
I vaccini per il controllo della fertilità a dose singola di SpayVac offrono un'alternativa alla triploidia nell'acquacoltura, con i primi studi di fattibilità che stanno avanzando alla seconda fase. La tecnologia utilizza una piattaforma brevettata a base di liposomi, dimostrando un'efficacia contraccettiva di 4-10 anni in diverse specie.
L'azienda sta perseguendo l'approvazione normativa per cavalli selvatici e popolazioni di cervi allo stato brado, con il Bureau of Land Management (BLM) degli Stati Uniti come potenziale cliente principale. Attualmente il BLM gestisce 53.797 cavalli allo stato brado, ben oltre il Livello di Gestione Appropriato di 22.637, spendendo il 66% del suo budget di 153 milioni di dollari per i costi di mantenimento a lungo termine.
BioVaxys Technology Corp. (BVAXF) y SpayVac for Wildlife han ampliado su Acuerdo de Licencia para incluir los mercados comerciales de acuicultura y peces de criadero. Esta expansión apunta a una oportunidad de mercado significativa en el salmón atlántico y la trucha arcoíris criados en granjas, con una cosecha anual aproximada de 3.28 millones de toneladas métricas (800 millones de peces individuales).
Las vacunas anticonceptivas de dosis única de SpayVac ofrecen una alternativa a la triploidía en acuicultura, con los ensayos iniciales de prueba de concepto avanzando a la segunda fase. La tecnología utiliza una plataforma patentada de liberación basada en liposomas, demostrando una eficacia contraceptiva de 4 a 10 años en diversas especies.
La compañía busca la aprobación regulatoria para caballos ferales y poblaciones de ciervos en libertad, con la Oficina de Administración de Tierras de EE.UU. (BLM) como posible cliente principal. Actualmente, el BLM gestiona 53,797 caballos en libertad, muy por encima del Nivel de Manejo Apropiado de 22,637, destinando el 66% de su presupuesto de 153 millones de dólares a costos de mantenimiento a largo plazo.
BioVaxys Technology Corp. (BVAXF)와 SpayVac for Wildlife는 상업용 양식 및 농장 양식 어류 시장을 포함하도록 라이선스 계약을 확장했습니다. 이번 확장은 연간 약 328만 메트릭톤(8억 마리)의 농장 양식 대서양 연어와 무지개송어 시장의 큰 기회를 겨냥합니다.
SpayVac의 단일 투여용 생식력 조절 백신은 양식업에서 삼배체 처리에 대한 대안으로, 초기 개념 증명 시험이 2단계로 진행 중입니다. 이 기술은 특허받은 리포좀 기반 전달 플랫폼을 사용하며, 다양한 종에서 4~10년간의 피임 효과를 입증했습니다.
회사는 야생 말과 자유 방목 사슴 개체군에 대한 규제 승인을 추진 중이며, 미국 토지관리국(BLM)이 잠재적 주요 고객입니다. 현재 BLM은 53,797마리의 야생 말을 관리하고 있으며, 적정 관리 수준인 22,637마리를 훨씬 초과해 1억 5,300만 달러 예산의 66%를 장기 보유 비용에 지출하고 있습니다.
BioVaxys Technology Corp. (BVAXF) et SpayVac for Wildlife ont élargi leur accord de licence pour inclure les marchés de l'aquaculture commerciale et des poissons d'élevage. Cette extension vise une opportunité de marché importante dans le saumon atlantique et la truite arc-en-ciel d'élevage, avec une récolte annuelle d'environ 3,28 millions de tonnes métriques (800 millions de poissons individuels).
Les vaccins de contrôle de fertilité à dose unique de SpayVac offrent une alternative à la triploïdie en aquaculture, les essais de preuve de concept initiaux progressant vers la deuxième phase. La technologie utilise une plateforme de délivrance brevetée à base de liposomes, démontrant une efficacité contraceptive de 4 à 10 ans chez diverses espèces.
L'entreprise poursuit l'approbation réglementaire pour les chevaux sauvages et les populations de cerfs en liberté, le Bureau de gestion des terres des États-Unis (BLM) étant un client potentiel principal. Le BLM gère actuellement 53 797 chevaux en liberté, bien au-dessus du niveau de gestion approprié de 22 637, consacrant 66 % de son budget de 153 millions de dollars aux coûts de détention à long terme.
BioVaxys Technology Corp. (BVAXF) und SpayVac for Wildlife haben ihre Lizenzvereinbarung erweitert, um den kommerziellen Aquakultur- und Zuchtfischmarkt einzubeziehen. Die Erweiterung zielt auf eine bedeutende Marktchance bei in Farmen gezüchtetem atlantischem Lachs und Regenbogenforelle ab, mit einer jährlichen Ernte von etwa 3,28 Millionen Tonnen (800 Millionen einzelne Fische).
Die Einzeldosis-Fruchtbarkeitskontrollimpfstoffe von SpayVac bieten eine Alternative zur Triploidie in der Aquakultur, wobei erste Machbarkeitsstudien in die zweite Phase übergehen. Die Technologie nutzt eine patentierte liposombasierte Lieferplattform und zeigt eine kontrazeptive Wirksamkeit von 4 bis 10 Jahren bei verschiedenen Arten.
Das Unternehmen strebt eine behördliche Zulassung für wilde Pferde und frei lebende Hirschpopulationen an, wobei das U.S. Bureau of Land Management (BLM) als potenzieller Hauptkunde gilt. Das BLM verwaltet derzeit 53.797 Wildpferde auf der Weide, was deutlich über dem angemessenen Managementniveau von 22.637 liegt, und verwendet 66 % seines Budgets von 153 Millionen US-Dollar für langfristige Haltungskosten.
- Expansion into commercial aquaculture opens significant new market opportunity with 800 million potential fish targets annually
- Single-dose, long-lasting (4-10 years) vaccine efficacy demonstrated across multiple species
- Potential revenue stream from BLM contract for managing 53,797 feral horses
- Advanced to second phase of development in aquaculture trials
- Regulatory approval still pending for initial products
- Efficacy in aquaculture market still unproven, with trials ongoing
Submission Process Underway for Regulatory Approval of SpayVac in Feral Horses and Free-Ranging Deer Populations
The global market for farm-raised Atlantic salmon and rainbow trout represents a significant commercial opportunity for SpayVac. According to Seafish, a
SpayVac vaccines offer a new and disruptive approach to immune-sterilization, rendering animals infertile with a single-dose product. This method is simple and economical. At the core of SpayVac's technology is a patented liposome-based delivery platform developed by BioVaxys and licensed to SpayVac, designed to create long-lasting, targeted immune responses. Composed of naturally occurring phospholipids, these liposomes encapsulate the antigen and improve the immune system's response to vaccination. Different antigens target different points in the reproductive system. For example, porcine Zona Pellucida (pZP) antibodies block sperm binding on the females' egg; and pZP vaccines have proven to be safe and effective in a wide range of species, including horses and deer.
Multiple clinical trials have demonstrated SpayVac-pZP's single-dose, long lasting (4-10 years) immunocontraceptive efficacy in different animals such as seals, feral horses, and several species of deer.1 Trials with farmed trout, macaques, and African and Asian elephants are ongoing.
Armed with the results from multiple studies completed in deer and horses, SpayVac has initiated the submission process to secure regulatory approval for its first product targeting feral horses and free-ranging deer populations, with the
Feral horses on public lands are protected and managed by the BLM and
The challenge of managing feral horse populations is not limited to
With its single dose and long duration of activity, SpayVac is anticipated to be a game-changer for immunocontraception. Current pZP-based immunocontraception products, like ZonaStat, require a booster 3–4 weeks after the initial inoculation and subsequent annual boosters to maintain contraceptive efficacy. Coupling horse removals with a single-dose, multi-year vaccine, such as SpayVac, will quickly and efficiently bring feral horse population numbers down and maintain them at appropriate management levels.
"We are extremely pleased and excited with the progress of SpayVac-for-Wildlife," says BioVaxys President and Chief Operating Officer Kenneth Kovan. "Based on the superior profile of SpayVac vaccines and the U.S. market potential with feral horses and deer, we are anticipating a healthy revenue stream from royalties on sales of SpayVac. With huge global markets for horses and deer, such as
- Bechert, U., and Fraker, M. 2018. Twenty years of SpayVac® research: potential implications for regulating feral horse and burro populations in
the United States . Human-Wildlife Interactions 12(1):117-130. - Accessed 4 April 2025: https://www.blm.gov/programs/wild-horse-and-burro/about-the-program/program-data.
- Accessed 16 April 2025: https://www.biovaxys.com/newsroom/
- Accessed 16 April 2025: https://invasives.org.au/?s=feral+horses.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated and unique mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, and DPX+rPA for peanut allergy prophylaxis, as well as several viral vaccines. BioVaxys has licensed its patented liposome-based delivery platform to Zoetis, Inc. and SpayVac-for-Wildlife, Inc. for selected animal health applications.
BioVaxys common shares are listed on the CSE under the stock symbol 'BIOV', trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
About SpayVac-for-Wildlife
SpayVac for Wildlife, Inc., (https://spayvac.com/) based in
ON BEHALF OF SPAYVAC FOR WILDLIFE,INC
Signed "Thomas D'Orazio"
Thomas D'Orazio, Chief Executive Officer
Cautionary Statements Regarding Forward Looking Information
This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.
The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Investors are encouraged to read BioVaxys continuous disclosure documents and audited annual consolidated financial statements which are available on SEDAR at www.sedar.com.
Logo: https://mma.prnewswire.com/media/2415135/5279107/BioVaxys_Technology_Corp_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/biovaxys-and-spayvac-for-wildlife-expand-license-agreement-into-commercial-aquaculture-302434429.html
SOURCE BioVaxys Technology Corp.
FAQ
What is the market potential for SpayVac's fertility control vaccines in aquaculture?
How long does BVAXF's SpayVac contraceptive effectiveness last in animals?
What is the current status of SpayVac's regulatory approval process for BVAXF?
How does BVAXF's SpayVac technology differ from current contraceptive products?
